Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with PNES had higher self-reported anxiety and depression levels (GAD-7: p = 0.04, PHQ-9: p < 0.01; BDI-II: p < 0.01) but similar QOL to PWE (p = 0.78).
|
31759316 |
2020 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the 336 usable responses, 16.1% scored 10 or greater on the PHQ-8 consistent with current depression while 17.3% scored 10 or greater on the GAD-7 consistent with current anxiety.
|
30637564 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary outcome measures were assessed with the Generalized Anxiety Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8), Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-1).
|
29351138 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> The study indicated that past-year Wave II financial mistreatment was associated with significantly increased likelihood of depression, PTSD, GAD, and poor self-rated health; and financial mistreatment perpetrated by family members was associated with particularly increased risk of depression.
|
29665715 |
2019 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Self-report questionnaires were administered to assess quality of life (12-item Kansas City Cardiomyopathy Questionnaire quality of life subscale), level of anxiety (7-item Generalized Anxiety Disorder; GAD-7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida Patient Acceptance Survey; FPAS) to 101 consecutive patients presenting to LVAD clinic.
|
31346241 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Item response theory-based linking methods were used to create crosswalk tables that convert scores on the GAD-7 to the TBI-QOL Anxiety metric and scores on the PHQ-9 to the TBI-QOL Depression metric.
|
31498233 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were also screened for depression using the Neurological Disorder Depression Inventory for Epilepsy (NDDI-E) and the Center for Epidemiologic Studies Depression Scale (CES-D) and for anxiety using the Generalized Anxiety Disorder-7 (GAD-7) scale.
|
31181426 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conclusions The results support the use of the PHQ-9 and GAD-7 as brief, easy-to-use screening measures that can be administered by physicians to rapidly identify acute distress and inform treatment recommendations among TGNC youth seeking medical intervention.
|
30530884 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hearing performance was assessed with Freiburg monosyllabic test and Oldenburg inventory (OI); the health-related quality of life was measured with Nijmegen Cochlear Implantation Questionnaire (NCIQ); depressive symptoms with General Depression Scale (ADS-L); stress with Perceived Stress Questionnaire (PSQ) and anxiety with General Anxiety Disorder-7 (GAD-7).
|
30870379 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a cross-sectional study, 23 patients with IPF were evaluated using Montreal Cognitive Assessment (MoCA), an instrument for detecting mild cognitive impairments and were screened for OSA through overnight cardiorespiratory polygraphy and for anxiety and depression with three specific scale (Generalized Anxiety Disorder 7-item scale: GAD-7; the Patient Health Questionnaire: PHQ-9; Hospital Anxiety and Depression Scale: HADS).
|
30707735 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in DEMS correlated with changes in both PHQ-8 and GAD-7 in the subgroup of patients without prior depression or anxiety diagnosis (ρ = 0.6, P = 0.002; ρ = 0.4, P = 0.02).
|
30950896 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PHQ-9 and GAD-7 were determined to be potential screening tools to aid Chinese medical workers in recognizing depression and anxiety in nonpsychiatric departments.
|
30762438 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical correlates of FoP were assessed via a variety of measures, including patients' physical state (Karnofsky Performance Status, KPS), cancer-related psychosocial distress (Distress Thermometer, DT), anxiety (General Anxiety Disorder Scale, GAD-7), depression (Patient Health Questionnaire, PHQ-9), Quality of Life (Short Form Health Survey, SF-8), and unmet supportive care needs (Supportive Care Needs Survey, SCNS).
|
30684045 |
2019 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the third trimester, a second FOBS score, and saliva sample were collected, and the Personal Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) were administered to measure depression and anxiety respectively.
|
31306998 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The GAD67-mediated depression became stable after 14 weeks.
|
30788386 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two scoring methods were used to convert the scores on the PHQ-9, GAD-7 and K6 to the PROMIS depression and anxiety metrics.
|
29872956 |
2018 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prevalence estimates for depressive disorder (CIDI), depressive symptoms (BDI ≥ 16), anxiety symptoms (GAD-7 ≥ 10) and PTSD (PCL-C DSM criteria) were 3.8, 5.9, 3.6, and 4.5% respectively for twins and 3.9, 9.8, 5.1 and 5.4% for singletons.
|
29343229 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
They completed the Centre for Epidemiologic Studies Depression Scale (CES-D) and the General Anxiety Disorder Scale (GAD-7) to measure whether they experience depression and/or anxiety symptoms.
|
29543833 |
2018 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Whereas cortical GAD67 reduction and subsequent GABA level decrease are consistently observed in schizophrenia and depression, it remains unclear how these GABAergic abnormalities contribute to specific symptoms.
|
29362511 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mean post treatment PHQ-9 and GAD-7 scores remained above threshold for those receiving CBT_DA but not those receiving CBT-D.
|
30048513 |
2018 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PWE from rural West China were evaluated for depression and anxiety with the Neurological Disorders Depression Inventory for Epilepsy (C-NDDI-E; Chinese version) and the Generalized Anxiety Disorder-7 (GAD-7; Chinese version).
|
30125939 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depression was more commonly studied (ranged from 1%-30%).Prevalence of GAD ranged from 1%-26%.
|
29966886 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Respectively 21.4% and 7.8% of the participants had depression and clinical symptoms of GAD.
|
30550597 |
2018 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meditation was associated with subjective benefits but no statistically significant effect on depression scores (change in PHQ-9, -3.0±3.9 in the intervention group versus -2.0±4.7 in controls; <i>P</i>=0.45) or anxiety scores (change in GAD-7, -0.9±4.6 versus -0.8±4.8; <i>P</i>=0.91).
|
29025788 |
2017 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Associations between non-disclosure and the following factors were established using modified Poisson regression with adjustment for socio-demographic factors (gender, age group, ethnicity), HIV-related factors (time since HIV diagnosis, ART status), and clinic: low social support (score ≤ 12 on modified Duke-UNC FSSQ); depression and anxiety symptoms (≥10 on PHQ-9 and GAD-7 respectively); self-reported ART non-adherence in past 2 weeks/3 months; VL non-suppression (clinic-recorded VL > 50 copies/mL among those who started ART ≥ 6 months ago).
|
27586375 |
2017 |